SPY756.50−0.44%QQQ683.64−0.98%BTC/USD72,695.00−1.67%DIA524.91+0.09%GLD360.58−1.26%TLT80.88−0.05%

Evommune Inc

EVMNNYSE

Trade with Public

$8.62

0.789.95%

Last update: Nov 12, 12:03 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Evommune (EVMN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Evommune (EVMN) stock.

Analyst Consensus — 12 Analysts

1S.Buy

10Buy

1Hold

# Analysts12

Latest Upgrades and Downgrades for Evommune Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Alice Nettleton	Initiate	Neutral	$8
—	Leerink Partners	Thomas Smith	PT Cut	Outperform	$28→$22
—	RBC Capital	Brian Abrahams	PT Cut	Outperform	$29→$21
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
—	Needham	Serge Belanger	Initiate	Buy	$28
—	RBC Capital	Brian Abrahams	PT Cut	Outperform	$30→$29
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
—	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$55→$26
—	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
—	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
—	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$50
—	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$54→$55
—	RBC Capital	Brian Abrahams	Maintained	Outperform	$48
—	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$65→$50
—	Clear Street	Kaveri Pohlman	Initiate	Buy	$53
—	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$35→$65
—	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$42
—	Raymond James	Martin Auster	Initiate	Strong Buy	$40
—	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$35
—	William Blair	Matt Phipps	Initiate	Outperform	—

Evommune Inc

Evommune (EVMN) Stock Price Target 2026

Latest Upgrades and Downgrades for Evommune Stock

Evommune (EVMN) Stock Price Target 2026

Latest Upgrades and Downgrades for Evommune Stock

Analyst Ratings News

PRO
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

People Also Watch

People Also Watch

Analyst Ratings News

PRO
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

Evommune Inc

Evommune (EVMN) Stock Price Target 2026

Latest Upgrades and Downgrades for Evommune Stock

Evommune (EVMN) Stock Price Target 2026

Latest Upgrades and Downgrades for Evommune Stock

Analyst Ratings News

PROUBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PROLeerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRORBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRONeedham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

People Also Watch

People Also Watch

Analyst Ratings News

PROUBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PROLeerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRORBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRONeedham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

PRO
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

PRO
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

PRO
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

PRO
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral

PRO
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28